Brought to you by 
Harvard University spin-off ReadCoor enters into exclusive license for gene sequencing technology
08 Jun 2022
Executive Summary
Concurrent with ReadCoor Inc.'s spin off from Harvard University's Wyss Institute, the company exclusively licensed the FISSEQ (fluorescent in situ sequencing) gene sequencing technology.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Harvard University spin-off ReadCoor enters into exclusive license for gene sequencing technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice